Best Life Sciences Platforms and Tools Companies in London, United Kingdom
The 64 best Life Sciences Platforms and Tools companies in London, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Oribiotech.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in London
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Oribiotech 🦄 Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool | $281M | 48 mo ago | 11 | Farlan Veraitch Co-Founder & Chief Scientific Officer | WordPressApple iCloud MailMicrosoft 365+26 | Series B | 252 patents Design and optimization of bioreactor systems for cell culture and bioprocessing | 1 launch · 1 partnership |
| 2 | Catapult Cell and Gene Therapy Works as an accelerator for new technologies and ideas | $127M | 64 mo ago | 164 | — | — | Funding Raised | — | — |
| 3 | Judges Scientific Acquisition and development of scientific instrument businesses | $62M | 97 mo ago | 622 | David Cicurel Co-Founder & CEO | Windows ServerBootstrapVimeo+18 | Public | — | — |
| 4 | Engitix Developer of technology for in vitro drug discovery 42Growth top 35%Talent top 38%Funding top 39%News top 43% All 10 signals ▾Growthtop 35% Talenttop 38% Fundingtop 39% Newstop 43% Patentstop 44% Moattop 47% Techtop 50% Innovationbottom 43% Globalbottom 42% Marketbottom 32% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $60M | 5 mo ago | 16 | Massimo Pinzani Co-Founder | WebflowApple iCloud MailGSAP+11 | Series A | 4 patents Patents concentrated in chemistry & materials | 1 partnership |
| 5 | Portal Biotech Developer of biosensing technology that utilizes bioengineered nanopores to analyze proteins and metabolomics | $45M | 14 mo ago | — | Giovanni Maglia Co-Founder | Apple iCloud MailMicrosoft 365Ruby+14 | Series A | 13 patents Nanopore-based biomolecular sensing and protein/ analyte detection technologies. | — |
| 6 | Femtogenix Provider of DNA-interactive payload molecules for use in ADCs | $40M | 51 mo ago | 14 | Chris Keightley CEO | — | Series B | 43 patents Design of piperidinobenzodiazepine small‑molecule cytotoxic agents for cancer therapy | — |
| 7 | uMed Provider of platform facilitating patient data access for life science research | $17M | 35 mo ago | 11 | Matt Wilson Founder & CEO | WordPressMySQLPHP+26 | Series A | — | 1 job opening |
| 8 | OxSyBio Provider of 3D printing of tissue biomaterials for medical research and clinical applications | $16M | 100 mo ago | 21 | John Bayley Co-Founder | — | Series A | — | — |
| 9 | Pear Bio Developer of microfluidic chip for cancer drug research | $14M | 38 mo ago | 18 | Duleek Ranatunga Founder & CEO | — | Series A | — | — |
| 10 | Quality by Design Developer and manufacturer biomaterials | $13M | 73 mo ago | 44 | — | DrupalPleskPHP+15 | Acquired | — | — |
| 11 | RwHealth Provider of an AI-based drug discovery platform | $10M | 24 mo ago | 23 | Scott Fletcher CEO | — | Deadpooled | — | — |
| 12 | GenDaq Developer of technologies for regulation of gene expression | $10M | 314 mo ago | 11 | Yen Choo Founder | — | Acqui-Hired | 48 patents Engineered DNA-binding proteins and peptide libraries for nucleic acid recognition applications. | — |
| 13 | Multus Provider of lab-grown meat alternatives | $9M | 41 mo ago | 8 | Kevin Pan Co-founder & CTO | — | Series A | — | — |
| 14 | MicrofluidX Provider of cell and gene based therapy | $9M | 32 mo ago | 10 | Antoine Espinet Co-Founder & CEO | — | Seed | 24 patents Microfluidic bioprocessing platforms for precise fluid handling and aseptic cell culture | — |
| 15 | Progenitor Labs Develops drugs to regenerate specific tissues of the human body in response to injury, disease or aging. | $6M | 159 mo ago | 1 | Yen Choo CEO | — | Series A | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 16 | Inexia Developer of orexin modulators for treating narcolepsy | $5M | 77 mo ago | 3 | — | — | Series A | — | — |
| 17 | Oxfordpharmascience Drug development company that re-develops approved drugs using proprietary formulation technologies | $5M | 151 mo ago | 2 | — | — | Public | — | — |
| 18 | Apta Biosciences Developer of a synthetic biology technology platform for diagnostics and therapeutics | $5M | 126 mo ago | 11 | William Addison Co-Founder & Director | — | Deadpooled | 12 patents Patents concentrated in chemistry & materials | — |
| 19 | Inoviv Provider of biomarker tests for precision treatments | $3M | 28 mo ago | 6 | Michael Dove Co-Founder & CEO | WordPressMySQLPHP+30 | Seed | — | — |
| 20 | Hyris Cloud-based software and genetic testing assay | $3M | 72 mo ago | 14 | Stefano Lo Priore CEO | JoomlaNode.jsPHP+12 | Series A | 16 patents Patents concentrated in computing, sensing & instrumentation | — |
| 21 | CC Bio Provider of synthetic biology platform for the development of drugs for microbiome-based diseases | $1M | 58 mo ago | 2 | Matthew Cummings Co-Founder & CEO | — | Acquired | — | — |
| 22 | Mursla Provider of diagnostic device for cancer detection | $547K | 69 mo ago | 9 | Victor Serdio Co-Founder | NicepageWordPressMySQL+15 | Seed | 32 patents Isolation, characterization, and biosensor conditioning of tissue-specific extracellular vesicles. | — |
| 23 | Equinox Pharma UK-based drug discovery CRO using machine learning for developing novel hits. | $324K | 113 mo ago | 3 | Stephen Muggleton Co-Founder | — | Deadpooled | — | — |
| 24 | Redd & Whyte Provider of non contact bulk reagent dispenser | $189K | 127 mo ago | 2 | Roger Poole CEO & Managing Director | — | Funding Raised | 7 patents Micro-scale fluid control valves for precision hydraulic and pneumatic systems | — |
| 25 | Cytera Developer of a device for automated cell culture | $150K | 94 mo ago | 41 | Ignacio Willats Co-Founder & COO | — | Seed | — | — |
| 26 | HelixNano Nanotechnology based solutions for DNA sequencing | $120K | 108 mo ago | 15 | Hannu Rajaniemi Co-Founder | — | Seed | — | — |
Top 12 Life Sciences Platforms and Tools companies in London
#1
Series A · London, England · founded 2016 · 16 employees$60.4Mraised▾
Developer of technology for in vitro drug discovery. The company's proprietary technology includes a human-derived biological scaffold for the development of 3D spheroids and tissue engineering systems. The applications of the technology include accelerating in vitro drug discovery and helping patients with end-stage liver disease. The company has also designed BAL to address the unmet need for treatment of liver failure, providing bedside support.
- Jan 2026Series A$25M
- Jan 2022Series A$54M
- Nov 2018Series A$6.4M
#2
Series A · London, England · founded 2021$45.4Mraised▾
Developer of biosensing technology that utilizes bioengineered nanopores to analyze proteins and metabolomics. It offers bench-top nanopore solutions for comprehensive, full–length, single-molecule protein characterisation which enables the real-time analysis of complex mixtures of biomolecules, providing rapid insights into protein abundance, identity, heterogeneity and variation.
- Apr 2025Series A$35M
- Jul 2022Series A$9.7M
- Jul 2021Seed$691.9K
#3
Series B · London, England · founded 2015 · 11 employees$281.1Mraised▾
Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool. The technology integrates bioreactor systems and sterile connection tools to facilitate the manufacturing of biological products. The equipment supports process control and scalability throughout the development cycle, from research stages to commercial production. The system design aims to improve reproducibility and throughput in the creation of therapeutic materials.
- Jun 2022Series B$138.7M
- Jan 2022Series B$102.5M
- Sep 2020Series A$30.5M
- Aug 2019Seed$9.4M
#4
Deadpooled · London, England · founded 2011 · 23 employees$10.2Mraised▾
Provider of an AI-based drug discovery platform. The company offers a Data Science Platform that develops real-time and predictive insights for complexities of disease and therapeutic development.
- Jun 2024Series A$1.8M
- Nov 2021Series A$8.5M
#5
Funding Raised · London, England · founded 2012 · 164 employees$127.1Mraised▾
The Cell and Gene Therapy Catapult is a not for profit organization, that works in collaboration with research institutes and universities to build their ideas into a product. It further partners with leading pharmaceutical companies for marketing and commercialization of the product.
- Feb 2021Grant (prize money)—
- Jul 2020Grant (prize money)$127M
- Mar 2019Grant (prize money)$60.3K
- Nov 2018Grant (prize money)—
#6
Series A · London, England · founded 2018 · 11 employees$17.4Mraised▾
Provider of platform facilitating patient data access for life science research. The platform enables researchers to access custom patient data and insights derived from electronic health records, clinical outcomes, and patient-generated data. It facilitates the creation of consented patient cohorts to accelerate research and generate insights. The platform is embedded across a network of healthcare institutions.
- Jul 2023Series A$12.5M
- Dec 2020Seed$4.9M
#7
Seed · London, England · founded 2018 · 10 employees$9.1Mraised▾
Operator of cell therapy research and manufacturing platform designed to make bio-processing scalable and affordable for cell and gene therapy. The company's platform specializes in tackling the problems of process control and scalability with cell bioprocessing in particular for autologous cell and gene therapy, enabling biologists to carry out process development by running cell culture conditions in parallel with extreme process control and to scale up cells for manufacturing at a lower cost.
#8
Series B · London, England · founded 2015 · 14 employees$40.2Mraised▾
Femtogenix, a spin-out company from King’s College London (KCL) is a drug discovery company focussed on developing DNA-interactive payload molecules for use in antibody-drug conjugates (ADCs). Its drug discovery platform claims to enable the design molecules which are capable of binding reversibly and/or irreversibly to DNA, in a sequence-interactive manner, leading to exquisite cytotoxicity toward tumor cells and when attached to antibodies, these potent cytotoxic agents can be delivered directly to tumors. It is currently looking for a partnership with pharmaceutical companies.
- Mar 2022Series B$36.6M
- Sep 2015Series A$3.6M
#9
Series A · London, England · founded 2017 · 18 employees$14.2Mraised▾
Pear Bio develops microfluidic chip for cancer drug research. The device combines tissue engineering, microfluidics, and biomaterials to represent how drugs are infused, distributed and exposed to the tumor over multiple passes during a chemo regimen. It also maps the spread of cancer using 3D imaging.
- Apr 2023Series A$14.2M
- Jan 2019Seed—
- 2017Grant (prize money)—
#10
Seed · London, England · founded 2017 · 6 employees$3.4Mraised▾
Provider of biomarker tests for precision treatments. The company offers biomarker tests to identify patients and demonstrate treatment efficacy for novel therapies. The company has laboratory manufacturing facilities certified by GLP and CLIA.
- Jan 2024Seed—
- Jan 2022Seed$2.5M
- Nov 2018Seed$984.8K
#11
Series A · London, England · founded 2019 · 8 employees$9.3Mraised▾
Provider of lab-grown meat alternatives. The company claims it is using cells from livestock animals and multiplying them in the laboratory to obtain whole cuts of meat.
- Jan 2023Series A$7M
- Jan 2023Grant (prize money)$2.5M
- Jul 2021Seed$2.1M
- Jul 2021Grant (prize money)$146K
#12
Public · London, England · founded 2002 · 622 employees$62.2Mraised▾
Acquisition and development of scientific instrument businesses. The company is dealing with their subsidiary companies specializing in the manufacturing of scientific instruments applicable in biotech companies and universities for research purpose. The subsidiary companies include Armfield, CoolLED, Deben, Dia-Stron, EWB Solutions, Fire Testing Technology, GDS Instruments, Oxford Cryosystems, and others.
- Apr 2018Conventional Debt$48.8M
- Oct 2013Post IPO$13.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in London is moving
A read on the academic research around Bioinformatics in London — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 658 papers.
- University College London180
- Imperial College London179
- King\'s College London143
- Queen Mary University of London81
- London School of Hygiene & Tropical Medicine33
- Genome3→21
- Inference1→8
- Population1→7
- Biomarker1→7
- Sequence (biology)1→6
- Disease3→29
- Gene2→17
- DNA methylation1→7
- Epigenetics1→5
- Cancer4→7
- Disease3→28
- Immune system1→8
- Context (archaeology)2→7
- Metabolite1→3
- Drug1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.